Skip to main content
SpringerLink
Log in

Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea

  • Brief Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Background

Whether antibiotic treatment in patients with enterohemorrhagic Escherichia coli (EHEC)-associated diarrhea influences the risk of hemolytic uremic syndrome (HUS) has still to be elucidated.

Patients and methods

During the EHEC epidemic which occurred in northern Germany in spring 2011, 24 patients with E. coli O104:H4 infection were treated at our hospitals, 19 of whom developed HUS. The use of antibiotics before and after the onset of HUS was documented, and the outcome in patients with and without antibiotic treatment was evaluated.

Results

Of the 24 patients with EHEC-associated diarrhea, seven received antibiotics before any signs of HUS were present (ciprofloxacin, cefotaxime, amoxicillin and/or metronidazole). Four of these seven patients (57 %) and 15 of the 17 patients (88 %) who were treated without antibiotics developed HUS (p = 0.12). Microbiological testing showed all E. coli O104:H4 to be extended-spectrum beta lactamase producers and thus susceptible only to fluoroquinolones, aminoglycosides and carbapenems. Two of the five patients (40 %) treated with ciprofloxacin and 17 of the 19 patients (89 %) treated without ciprofloxacin developed HUS (p = 0.043).

Conclusion

In our E. coli O104:H4-infected patients, treatment of diarrhea with antibiotics did not increase the risk of HUS. Significantly fewer patients treated with ciprofloxacin developed HUS than patients who did not receive ciprofloxacin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin–producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365:1771–80.

    Article  PubMed  CAS  Google Scholar 

  2. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930–6.

    Article  PubMed  CAS  Google Scholar 

  3. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis. A meta-analysis. JAMA. 2002;288:996–1001.

    Article  PubMed  Google Scholar 

  4. Phillips B, Tyerman K, Whiteley SM. Use of antibiotics in suspected haemolytic-uraemic syndrome—evidence based case report. Br Med J. 2005;330:409–10.

    Article  Google Scholar 

  5. Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006;24:731–42.

    Article  PubMed  CAS  Google Scholar 

  6. Robert Koch Institute (RKI). Available at: http://www.rki.de/DE/Content/InfAZ/E/EHEC/Falldefinition.pdf.

  7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Approved standard CLSI document M100-S21. CLSI, Wayne, 2011.

  8. Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. Br Med J. 2012;345:e4565.

    Article  Google Scholar 

  9. Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis. 2012;54:1413–21.

    Article  PubMed  Google Scholar 

  10. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012;55:33–41.

    Article  PubMed  CAS  Google Scholar 

  11. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J. 2012;31:37–41.

    Article  PubMed  Google Scholar 

  12. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection. 1992;20:25–9.

    Article  PubMed  CAS  Google Scholar 

  13. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H. Epidemic Escherichia coli O104:H4: effects of antibiotics on Shiga toxin 2 production and bacteriophage induction. Antimicrob Agents Chemother. 2012;56:3277–82.

    Article  PubMed  CAS  Google Scholar 

  14. Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sörgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2003;47:3789–94.

    Article  PubMed  CAS  Google Scholar 

  15. Isogai E, Isogai H, Hayashi S, Kubota T, Kimura K, Fujii N, Ohtani T, Sato K. Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol Immunol. 2000;44:89–95.

    PubMed  CAS  Google Scholar 

  16. Shiomi M, Togawa M, Fujita K, Murata R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Int. 1999;41:228–32.

    Article  PubMed  CAS  Google Scholar 

  17. Borgatta B, Kmet-Lunaček N, Rello J. E. coli O104:H4 outbreak and haemolytic-uraemic syndrome. Med Intensiva. 2012. doi:10.1016/j.medin.2011.11.022.

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Tropical Medicine and Infectious Diseases, University Hospital Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany

    H. F. Geerdes-Fenge, M. Löbermann, M. Nürnberg, C. Fritzsche & E. C. Reisinger

  2. Department of Medicine, Section of Nephrology, University Hospital Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany

    S. Koball & S. Mitzner

  3. Department of Medicine, Intensive Care Medicine, University Hospital Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany

    J. Henschel

  4. Pediatric Department, University Hospital Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany

    R. Höhn

  5. Department of Medicine, Klinikum Südstadt Rostock, Südring 81, 18059, Rostock, Germany

    H. C. Schober

  6. Department of Clinical Microbiology and Hygiene, University Hospital Rostock, Schillingallee 70, 18057, Rostock, Germany

    A. Podbielski

Authors
  1. H. F. Geerdes-Fenge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Löbermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Nürnberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Fritzsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Koball
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Henschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Höhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. C. Schober
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Mitzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Podbielski
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E. C. Reisinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. C. Reisinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geerdes-Fenge, H.F., Löbermann, M., Nürnberg, M. et al. Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea. Infection 41, 669–673 (2013). https://doi.org/10.1007/s15010-012-0387-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-012-0387-6

Keywords

Search

Navigation